Rallybio annual stock-based compensation
2020
2021
2022
2023
2024
2025
Rallybio Stock-Based Compensation Growth & History (RLYB)
Rallybio's stock-based compensation was $5.3M for fiscal 2025.
View full Rallybio company overviewRallybio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.3M | −$2.7M | −33.52% |
| 2024 | 2024-12-31 | $8.0M | −$2.9M | −26.80% |
| 2023 | 2023-12-31 | $10.9M | $1.4M | +14.96% |
| 2022 | 2022-12-31 | $9.5M | $5.9M | +160.60% |
| 2021 | 2021-12-31 | $3.6M | $2.9M | +417.76% |
| 2020 | 2020-12-31 | $704,000 | — | — |
Rallybio quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $424,000 | −$1.2M | −73.73% |
| Q1 2026 | 2026-03-31 | $613,000 | −$1.3M | −67.38% |
| Q4 2025 | 2025-12-31 | $774,000 | −$1.2M | −60.57% |
| Q3 2025 | 2025-09-30 | $1.0M | −$980,000 | −48.35% |
| Q2 2025 | 2025-06-30 | $1.6M | −$301,000 | −15.72% |
| Q1 2025 | 2025-03-31 | $1.9M | −$209,000 | −10.01% |
| Q4 2024 | 2024-12-31 | $2.0M | −$586,000 | −22.99% |
| Q3 2024 | 2024-09-30 | $2.0M | −$607,000 | −23.04% |
| Q2 2024 | 2024-06-30 | $1.9M | −$777,000 | −28.86% |
| Q1 2024 | 2024-03-31 | $2.1M | −$957,000 | −31.43% |
| Q4 2023 | 2023-12-31 | $2.5M | $255,000 | +11.12% |
| Q3 2023 | 2023-09-30 | $2.6M | $130,000 | +5.19% |
| Q2 2023 | 2023-06-30 | $2.7M | $45,000 | +1.70% |
| Q1 2023 | 2023-03-31 | $3.0M | $991,000 | +48.25% |
| Q4 2022 | 2022-12-31 | $2.3M | $765,000 | +50.03% |
| Q3 2022 | 2022-09-30 | $2.5M | $1.4M | +137.35% |
| Q2 2022 | 2022-06-30 | $2.6M | $2.1M | +391.09% |
| Q1 2022 | 2022-03-31 | $2.1M | $1.5M | +293.49% |
| Q4 2021 | 2021-12-31 | $1.5M | — | — |
| Q3 2021 | 2021-09-30 | $1.1M | $779,000 | +282.25% |
| Q2 2021 | 2021-06-30 | $539,000 | $445,000 | +473.40% |
| Q1 2021 | 2021-03-31 | $522,000 | — | — |
| Q3 2020 | 2020-09-30 | $276,000 | — | — |
| Q2 2020 | 2020-06-30 | $94,000 | — | — |
Rallybio stock-based compensation trends
Over the last five fiscal years, Rallybio's stock-based compensation increased from $704,000 to $5.3M, a change of $4.6M. The latest reported quarter, Q2 2026, shows $424,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rallybio source filings ↗